Difference between revisions of "Dermatofibrosarcoma protuberans"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
| Line 54: | Line 54: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''EORTC 62027:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/ | + | # '''EORTC 62027:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00085475 Clinical Trial Registry] |
| − | # '''SWOG S0345:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/ | + | # '''SWOG S0345:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00084630 Clinical Trial Registry] |
[[Category:Dermatofibrosarcoma protuberans regimens]] | [[Category:Dermatofibrosarcoma protuberans regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Soft tissue sarcomas]] | [[Category:Soft tissue sarcomas]] | ||
Revision as of 01:36, 25 June 2023
Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
2 variants on this page
|
Guidelines
NCCN
Older
- 2014: Bichakjian et al. Dermatofibrosarcoma protuberans, version 1.2014 PubMed
All lines of therapy
Imatinib monotherapy
Regimen variant #1, 400 mg/day
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Rutkowski et al. 2010 (SWOG S0345) | 2005-2006 | Phase 2, <20 pts |
Regimen variant #2, 800 mg/day
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Rutkowski et al. 2010 (EORTC 62027) | 2004-2007 | Phase 2, <20 pts (RT) |
Targeted therapy
- Imatinib (Gleevec) 400 mg PO twice per day
Continued indefinitely, unless complete (R0) surgical resection became possible
References
- EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed Clinical Trial Registry
- SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed Clinical Trial Registry